- Home
- LOMA vs NEO Comparison
LOMA vs NEO Comparison
Compare LOMA & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOMA | NEO |
|---|---|---|
| Founded | 1926 | 2001 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2017 | 1999 |
Fundamental Metrics
Financial Performance| Metric | LOMA | NEO |
|---|---|---|
| Price | $12.06 | $12.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $15.00 | $11.38 |
| AVG Volume (30 Days) | 289.0K | ★ 2.0M |
| Earning Date | 03-05-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $464,306,268.00 | ★ $709,162,000.00 |
| Revenue This Year | $22.92 | $10.90 |
| Revenue Next Year | $25.84 | $9.85 |
| P/E Ratio | $197.77 | ★ N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $7.04 | $4.72 |
| 52 Week High | $14.17 | $15.32 |
Technical Indicators
Market Signals| Indicator | LOMA | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 58.15 |
| Support Level | $11.25 | $12.29 |
| Resistance Level | $12.50 | $13.29 |
| Average True Range (ATR) | 0.54 | 0.65 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 43.10 | 57.46 |
Price Performance
Historical ComparisonAbout LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.